BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
MWN-AI** Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) announced that it will present four abstracts at the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 17-22, 2026, at the San Diego Convention Center in California. The accepted abstracts focus on the company's innovative cellular immunotherapy platform and highlight significant ongoing research, including a pivotal Phase 3 study examining Bria-IMT in combination with an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612). Additionally, research supporting Bria-OTS+, BriaCell's next-generation personalized off-the-shelf immunotherapy program, will be showcased.
The specific titles and presentation details of the posters will be available on March 17, 2026, at 4:30 PM ET, coinciding with the publication of the abstracts in the online Proceedings of AACR. BriaCell emphasizes its commitment to transforming cancer care through innovative therapies, positioning itself at the forefront of clinical-stage biotechnology.
As a disclaimer, the press release includes forward-looking statements that are inherently subject to numerous risks and uncertainties. These statements encompass assumptions regarding future events that may not materialize as predicted, underlining the unpredictable nature of clinical research and development. Investors are encouraged to review BriaCell's risk factors detailed in its Management's Discussion and Analysis and other filings available on SEDAR+ and EDGAR to fully understand potential risks.
With the information provided, both the scientific community and investors can anticipate advancements from BriaCell as it endeavors to contribute meaningfully to cancer treatment innovations. For further details, stakeholders can access BriaCell's official communications or direct inquiries to the company.
MWN-AI** Analysis
As BriaCell Therapeutics Corp. prepares to present four poster presentations at the highly esteemed AACR Annual Meeting in April 2026, potential investors should closely monitor the developments surrounding the company's transformative immunotherapy platforms. BriaCell, which is currently focused on advancing its flagship Bria-IMT in combination with immune checkpoint inhibitors and its innovative Bria-OTS personalized therapy, represents a critical player in the oncology space.
The upcoming presentations are pivotal for the company. Positive data dissemination could significantly elevate investor confidence and potentially drive stock prices higher. Given that BriaCell is in the midst of a pivotal Phase 3 study (ClinicalTrials.gov identifier: NCT06072612), any favorable outcomes shared during the conference could act as a catalyst, attracting new investors and analysts eager to assess the viability of Bria-IMT in a competitive market.
However, it is essential for investors to acknowledge the inherent risks outlined in BriaCell's forward-looking statements. The biotech sector is rife with uncertainties, especially in clinical trial outcomes and regulatory approvals. Investors should adopt a cautious approach, closely scrutinizing not only the clinical results but also potential market reactions and the broader economic environment.
In light of these factors, potential investors might consider the following strategies:
1. **Monitor Clinical Outcomes**: Track the results of BriaCell’s presentations at AACR, paying attention to both the clinical efficacy and safety data released.
2. **Risk Assessment**: Evaluate the company's financial health and assess potential risks in light of the recent market volatility and interest rates, which can impact speculative investments.
3. **Diversification**: Given the unpredictable nature of biotech stocks, ensure a diversified investment portfolio to mitigate risks associated with high volatility.
In conclusion, while BriaCell offers an exciting opportunity within immunotherapy, investors should remain diligent and proactive in their analysis leading up to and following the AACR presentations.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that four abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place from April 17th – 22nd at San Diego Convention Center, San Diego, CA.
The accepted abstracts highlight research related to BriaCell’s cellular immunotherapy platform, including the Company’s ongoing pivotal Phase 3 study of Bria-IMT?? in combination with an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612) and research supporting Bria-OTS+??, BriaCell’s next-generation personalized off-the-shelf immunotherapy program.
Poster titles and presentation details will become available on March 17, 2026 at 4:30 PM ET, when the abstracts will be published in the online Proceedings of AACR.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about presenting four posters at the 2026 AACR, the contents of such posters, and the expected disclosure of clinical data from its ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor and preclinical data for Bria-OTS+, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
FAQ**
How does BriaCell Therapeutics Corp. plan to leverage the results from the AACR presentations to enhance the value of their Warrant BCTXW for potential investors in Philadelphia and Vancouver?
What clinical milestones related to BriaCell's immunotherapies, including the BriaCell Therapeutics Corp. Warrant BCTXW, can investors expect to hear about during the AACR Annual Meeting in San Diego?
In what ways could the advancements in BriaCell Therapeutics Corp., particularly concerning Warrant BCTXW, influence investor sentiment in both Philadelphia and Vancouver's biotech sectors?
How does BriaCell intend to communicate ongoing developments and data from their pivotal Phase 3 study, including its impact on Warrant BCTXW, to stakeholders in Philadelphia and Vancouver following the AACR event?
**MWN-AI FAQ is based on asking OpenAI questions about Briacell Therapeutics Corp. (TSXC: BCT:CC).
NASDAQ: BCT:CC
BCT:CC Trading
-0.24% G/L:
$8.35 Last:
2,600 Volume:
$8.37 Open:
